Publications by authors named "Alexei Plotnikov"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,085

Total Likes

92

Extended Reach

145,227

Social Features

26
Q
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation.
Wangda Zhou, Emily Bozenhardt, Gregory E Alexander, Matthew L Zierhut, Samira Merali, Alexei N Plotnikov

Clin Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).
C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee, Alexei N Plotnikov

Am Heart J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults.
Zhu Luo, Jie Wang, Zhuolu Niu, Cuili Hu, Madhu Chintala, Alexei N Plotnikov

Drug Des Devel Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
Sneha S Jain, Kenneth W Mahaffey, Karen S Pieper, Wataru Shimizu, Tatjana Potpara, Alexei N Plotnikov

Am Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial.
Gerald Chi, Fahad AlKhalfan, Jane J Lee, Sahar Memar Montazerin, Clara Fitzgerald, Alexei Plotnikov

Front Cardiovasc Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial).
Fahad Alkhalfan, Tarek Nafee, Megan K Yee, Gerald Chi, Arzu Kalayci, Alexei Plotnikov

Am J Cardiol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Thomas J Povsic, E Magnus Ohman, Matthew T Roe, Jennifer White, Frank W Rockhold, Alexei N Plotnikov

JAMA Cardiol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Serge Korjian, Eugene Braunwald, Yazan Daaboul, Freek Verheugt, Christoph Bode, Alexei Plotnikov

Eur Heart J Acute Cardiovasc Care· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photoluminescence properties of self-assembled chitosan-based composites containing semiconductor nanocrystals.
Nina Slyusarenko, Marina Gerasimova, Alexei Plotnikov, Nikolai Gaponik, Evgenia Slyusareva

Phys Chem Chem Phys· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Serge Korjian, Eugene Braunwald, Yazan Daaboul, Michael Mi, Deepak L Bhatt, Alexei N Plotnikov

Am J Cardiol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).
Fahad AlKhalfan, Mathieu Kerneis, Tarek Nafee, Megan K Yee, Gerald Chi, Alexei Plotnikov

Am J Cardiol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome.
Yazan Daaboul, Serge Korjian, Alexei N Plotnikov, Paul Burton, Eugene Braunwald

J Am Coll Cardiol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
E Magnus Ohman, Matthew T Roe, P Gabriel Steg, Stefan K James, Thomas J Povsic, Alexei Plotnikov

Lancet· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The treatment of missing data in a large cardiovascular clinical outcomes study.
Roderick J Little, Julia Wang, Xiang Sun, Hong Tian, Eun-Young Suh, Alexei Plotnikov

Clin Trials· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Thomas J Povsic, Matthew T Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov

Am Heart J· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.
Ivo P Nnane, Alexei H Plotnikov, Gary Peters, Maureen Johnson, Clare Kojak

Clin Pharmacokinet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Characterization of Chitosan-Based Polyelectrolyte Complexes Doped with Xanthene Dyes.
Evgenia Slyusareva, Marina Gerasimova, Vitaliy Slabko, Nina Abuzova, Alexei Plotnikov

Chemphyschem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
Matthew A Cavender, C Michael Gibson, Eugene Braunwald, Stephen D Wiviott, Sabina A Murphy, Alexei N Plotnikov

Eur Heart J Acute Cardiovasc Care· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of major nonmetallic impurities in magnesium by glow discharge mass spectrometry with a fast flow source using sintered and pressed powder samples.
Alexei Plotnikov, Jens Pfeifer, Silke Richter, Heinrich Kipphardt, Volker Hoffmann

Anal Bioanal Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Sabina A Murphy, Alexei Plotnikov

Am J Cardiol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Jessica L Mega, Eugene Braunwald, Sabina A Murphy, Alexei N Plotnikov, Paul Burton

J Am Coll Cardiol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
Xu Steven Xu, Kenneth Moore, Paul Burton, Kim Stuyckens, Wolfgang Mueck, Alexei Plotnikov

Br J Clin Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Kenneth Todd Moore, Alexei Nikolaevich Plotnikov, An Thyssen, Nicole Vaccaro, Jay Ariyawansa

J Cardiovasc Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
C Michael Gibson, Jessica L Mega, Paul Burton, Shinya Goto, Freek Verheugt, Alexei Plotnikov

Am Heart J· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis